CCR2 and benign prostatic hyperplasia: In our laboratory, research has been carried out with important contributions in the field of biomarkers for prostate cancer and benign prostatic hyperplasia, such as associations with polymorphisms in the apoptosis genes BCL-2, FASL and BAX (da Silva Lawisch et al., 2022), HLA-G variant (Zambra et al., 2016) and polymorphisms in the CCR2 and CCR5 genes (Zambra et al., 2013).